A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

Phase 1

VX-828A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT06861413

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

VX-828

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2025-05-02.